Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2025)

Historic EBT Margin for Catalyst Pharmaceuticals (CPRX) over the last 11 years, with Q3 2025 value amounting to 47.87%.

  • Catalyst Pharmaceuticals' EBT Margin rose 34200.0% to 47.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 49.43%, marking a year-over-year increase of 84300.0%. This contributed to the annual value of 43.98% for FY2024, which is 202500.0% up from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' EBT Margin is 47.87%, which was up 34200.0% from 47.28% recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' EBT Margin registered a high of 54.33% during Q4 2022, and its lowest value of 37.03% during Q3 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' median EBT Margin value was 44.45% (recorded in 2024), while the average stood at 39.86%.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' EBT Margin plummeted by -824600bps in 2023 and then surged by 814800bps in 2024.
  • Catalyst Pharmaceuticals' EBT Margin (Quarter) stood at 33.45% in 2021, then soared by 62bps to 54.33% in 2022, then decreased by -22bps to 42.24% in 2023, then grew by 24bps to 52.31% in 2024, then dropped by -8bps to 47.87% in 2025.
  • Its last three reported values are 47.87% in Q3 2025, 47.28% for Q2 2025, and 50.41% during Q1 2025.